[Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018003910
German
Original Title: Pembrolizumab (Urothelkarzinom Erstlinientherapie) - Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung)
Details
Project Status: Completed
Year Published: 2021
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Urologic Neoplasms
  • Carcinoma, Transitional Cell
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Immune Checkpoint Inhibitors
Keywords
  • Pembrolizumab
  • Urologic Neoplasms
  • Carcinoma - Transitional Cell
  • Benefit Assessment
  • NCT02853305
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.